Aida Hanum Ghulam Rasool

Aida Hanum Ghulam Rasool

Auto-generated profile, based on publicly available information

Aida Hanum Ghulam Rasool

Pharmacology Vascular Laboratory, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
ARAida Hanum Ghulam Rasool
Aida Hanum Ghulam Rasool
ARAbd. Rashid Abd. Rahman
Abd. Rashid Abd. Rahman
KYKah Hay Yuen
Kah Hay Yuen
AWAbdul Rahim Wong
Abdul Rahim Wong

1 January 2006 in Journal of Nutritional Science and Vitaminology
Verified
Journal Article
Open access
PDF file
ARAida H. G. Rasool
Aida H. G. Rasool
KYKah H. Yuen
Kah H. Yuen
KYKhalid Yusoff
Khalid Yusoff
AWAbdul R. Wong
Abdul R. Wong
ARAbdul R. A. Rahman
Abdul R. A. Rahman
Tocotrienols are a class of vitamin E reported to be potent antioxidants, besides having the ability to inhibit the HMG-CoA reductase enzyme. This study assessed the effects of 3 doses of tocotrienol-rich vitamin E (TRE) on plasma tocotrienol isomer concentration, arterial compliance, plasma total antioxidant status (TAS), aortic systolic blood pressure (ASBP), serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in healthy males. Methodology: This randomised, blinded end-point, placebo-controlled clinical trial with a parallel design involved 36 healthy male subjects who took either an oral placebo or TRE at doses of 80, 160 or 320 mg daily for 2 mo. Baseline and end-of-treatment measurements of vitamin E concentration, arterial compliance [assessed by aortic femoral pulse wave velocity (PWV) and augmentation index (AI)], ASBP, plasma TAS, serum TC and LDL-C were taken. Results: Baseline tocotrienol isomer concentrations were low and not detectable in some subjects. Upon supplementation, all TRE-treated groups showed significant difference from placebo for their change in α, γ and δ tocotrienol concentrations from baseline to end of treatment. There was a linear dose and blood level relationship for all the isomers. There was no significant difference between groups for their change in PWV, AI, plasma TAS, ASBP, TC or LDL-C from baseline to end of treatment. Groups 160 mg (p=0.024) and 320 mg (p=0.049) showed significant reductions in their ASBP. Group 320 mg showed a significant 9.2% improvement in TAS. Conclusion: TRE at doses up to 320 mg daily were well tolerated. Treatment significantly increased α, δ, and γ tocotrienol concentrations but did not significantly affect arterial compliance, plasma TAS, serum TC or LDL-C levels in normal subjects.

19 February 2004 in Journal of Human Hypertension
Verified
Journal Article
Closed access
ARA H G Rasool
A H G Rasool
ARA R A Rahman
A R A Rahman
SCS R Choudhury
S R Choudhury
RSR B Singh
R B Singh

1 December 2003 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
ARA.H.G. Rasool
A.H.G. Rasool
ARA. Rehman
A. Rehman
WYWan Nazirah Wan Yusuf
Wan Nazirah Wan Yusuf
ARA.R.A. Rahman
A.R.A. Rahman
Arterial stiffness is emerging as a useful index of vascular health. Postmenopausal women have been shown to have stiffer arteries. Hormone replacement therapy and soy isoflavones improve arterial stiffness in these women. The aim of this study is to establish whether vitamin E improves arterial stiffness in postmenopausal women after 10 weeks of supplementation. Twenty postmenopausal women with a mean age of 54.59 +/- 1.22 years participated in this randomized, crossover, double-blind, placebo-controlled clinical trial. All women received 400 IU of tocopherol daily for 10 weeks or a placebo capsule, before being crossed over for treatment. At intervals of 5 weeks, subjects attended sessions where measurements of arterial stiffness, blood pressure and plasma vitamin E level were taken. Pulse wave velocity measurement, using the automated Complior machine, was used as an index of arterial stiffness. Plasma vitamin E level was 30.38 +/- 1.56 micromol/l at baseline, after treatment it was 59.01 +/- 3.30 micromol/l and 31.17 +/- 1.37 micromol/l with vitamin E and placebo, respectively (p < 0.001). There was no significant difference in pulse wave velocity after 10-week treatment with placebo and vitamin E (9.14 +/- 0.29 versus 9.04 +/- 0.29 m/s, respectively). Similarly, no difference in systolic and diastolic blood pressure was seen between placebo and vitamin E at the end of 10 weeks. Supplementary vitamin E for 10 weeks at 400 IU daily has no effect on arterial stiffness in healthy postmenopausal women.

1 January 2013 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SMSiti Safiah Mokhtar
Siti Safiah Mokhtar
PVPaul M. Vanhoutte
Paul M. Vanhoutte
SLSusan W.S. Leung
Susan W.S. Leung
MYMohd Imran Yusof
Mohd Imran Yusof
WSWan Azman Wan Sulaiman
Wan Azman Wan Sulaiman
ARAida Hanum Ghulam Rasool
Aida Hanum Ghulam Rasool
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

11 May 2015 in Clinical Hemorheology and Microcirculation
Verified
Journal Article
Closed access
PDF file
BABelqes Abdullah Mohammad Al-Tahami
Belqes Abdullah Mohammad Al-Tahami
AIAb Aziz Al-Safi Ismail
Ab Aziz Al-Safi Ismail
YBYvonne Tee Get Bee
Yvonne Tee Get Bee
SASiti Azima Awang
Siti Azima Awang
WRWan Rimei Salha Wan Abdul Rani
Wan Rimei Salha Wan Abdul Rani
ARAida Hanum Ghulam Rasool
Aida Hanum Ghulam Rasool
INTRODUCTION: Obesity is associated with impaired microvascular endothelial function. We aimed to determine the effects of orlistat and sibutramine treatment on microvascular endothelial function, anthropometric and lipid profile, blood pressure (BP), and heart rate (HR). METHODS: 76 subjects were recruited and randomized to receive orlistat 120 mg three times daily or sibutramine 10 mg daily for 9 months. Baseline weight, BMI, BP, HR and lipid profile were taken. Microvascular endothelial function was assessed using laser Doppler fluximetry and iontophoresis process. Maximum change (max), percent change (% change) and peak flux (peak) in perfusion to acetylcholine (ACh) and sodium nitroprusside (SNP) iontophoresis were used to quantify endothelium dependent and independent vasodilatations. RESULTS: 24 subjects in both groups completed the trial. After treatment, weight and BMI were decreased for both groups. ACh max , ACh % change and ACh peak were increased in orlistat-treated group but no difference was observed for sibutramine-treated group. BP and total cholesterol (TC) were reduced for orlistat-treated group. HR was reduced for orlistat-treated group but was increased in sibutramine-treated group. CONCLUSION: 9 months treatment with orlistat significantly improved microvascular endothelial function. This was associated with reductions in weight, BMI, BP, HR, TC and low density lipoprotein cholesterol. No effect was seen in microvascular endothelial function with sibutramine.